近年来,免疫治疗已成为晚期肺癌新的研究方向.其中免疫检查点抑制药的重要性凸显,主要包括细胞毒性T淋巴细胞相关抗原4抑制药与程序性细胞死亡蛋白-1及其配体(PD-L1)抑制药,尤其是后者已在晚期非小细胞肺癌一线及二线治疗中取得了突破性进展.%In recent years, immunotherapy has become a new research direction of lung cancer. Immune checkpoint inhibitors (ICIs) including cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors, programmed death-1 (PD-1) and its ligand (PD-Ll) inhibitors are becoming more and more important, which have achieved a success in the first-line or second-line treatment for non-small cell lung cancer.
展开▼
